DAFNA Capital Management LLC - 09 Nov 2026 Form 4 Insider Report for Stereotaxis, Inc. (STXS)

Reporting relationship: 10%+ Owner
Issuer ticker: STXS
Reported as of: 09 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Nov 2026, 16:01:21 UTC
Source filing: View source filing
Reporting owner signature: DAFNA Capital Management, LLC By: /s/ Dr. Nathan Fischel

Filing notes and source

Key filing fact

DAFNA Capital Management LLC filed Form 4 for Stereotaxis, Inc. (STXS) on 12 Nov 2026.

Key facts

This page summarizes DAFNA Capital Management LLC's Form 4 filing for Stereotaxis, Inc. (STXS).
1 reported transaction and 2 derivative rows are listed below.
Accepted by SEC: 12 Nov 2026, 16:01.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001389933 Primary reporting owner

DAFNA Capital Management LLC

Relationship: 10%+ Owner
Address: 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES
Signature: DAFNA Capital Management, LLC By: /s/ Dr. Nathan Fischel
Signature date: 12 Nov 2026

CIK 0001733969

Ghodsian Fariba Fischel

Relationship: 10%+ Owner
Address: C/O DAFNA CAPITAL MANAGEMENT, LLC, 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES
Signature: By: /s/ Dr. Fariba Ghodsian
Signature date: 12 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STXS transaction Derivative

Convertible Promissory Notes

Purchase

Transaction value
Shares
Change %
Price
Shares after: $2,000,000
Date: 09 Nov 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 1,652,892
Exercise price
Footnotes: F1, F2, F3, F4

STXS transaction Derivative

Convertible Promissory Notes

Purchase

Transaction value
Shares
Change %
Price
Shares after: $2,000,000
Date: 09 Nov 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 1,652,892
Exercise price
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

On November 9, 2026, the Issuer entered into a note purchase agreement (the "Purchase Agreement") with certain investors, including DAFNA Capital Management, LLC ("DAFNA"), on behalf of DAFNA LifeScience, L.P. and DAFNA LifeScience Select, L.P. (the "Funds"), for the purchase of convertible promissory notes (the "Notes"). DAFNA acquired Notes under the Purchase Agreement in the aggregate principal amount, and for a total purchase price, of $2,000,000. The Notes have a maturity date of November 9, 2029 and bear interest at a rate of 10% per annum, which may be paid in cash or in kind be adding the amount of interest to the principal balance.

Footnote F2

The conversion of the Notes will be made based on a conversion rate of $1.21 per share.

Footnote F3

The Notes and accrued interest are convertible into shares of the Issuer's Common Stock at the election of the holders at any time prior to the maturity date or the consummation of a merger, sale, consolidation or reorganization of the Issuer, subject to a 19.9% beneficial ownership blocker. If the Notes cannot be fully converted due to the NYSE American exchange cap, then no portion of the Notes will convert into the Issuer's Common Stock until the Issuer has obtained stockholder approval to the waiver of the exchange cap.

Footnote F4

The reported securities are directly owned by the Funds. DAFNA may be deemed to beneficially own the reported securities as the investment manager and general partner of the Funds. The reported securities may also be deemed beneficially owned by Dr. Fariba Ghodsian as the Chief Investment Officer of DAFNA. DAFNA and Dr. Ghodsian disclaim beneficial ownership of the reported securities except to the extent of its and her respective pecuniary interest therein, if any. This report shall not be deemed an admission that DAFNA or Dr. Ghodsian is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.